Analysis of the immunohistochemical expressions of p53, bcl-2 and Ki-67 in colorectal adenocarcinoma and their correlations with the prognostic factors

Abstract

-Context -Search of tumors markers that allow treatment with higher survival rates, and indicate the response to treatment and recurrence of cancer -Objective -To analyze the immunoexpression of the proteins p53, bcl-2 and Ki-67 in colorectal adenocarcinoma and correlate them with the clinical-pathological prognostic factors. Method -Tissue microarray paraffin blocks were made from colorectal adenocarcinoma tissue resected from 82 patients who had undergone surgery but not chemotherapy or radiotherapy, at "Hospital São Paulo", São Paulo, SP, Brazil, between 2002 and 2005. Thin sections (4 μm) were subjected to immunohistochemical reactions, and immunoexpression staining scores were obtained. The scores were correlated with the degree of cell differentiation, staging, disease-free interval, recurrence, survival and specific mortality. The study variables were analyzed using the chi-square and Kaplan-Meier tests to investigate associations with the markers. The significance of the differences between the curves of the diseasefree interval and survival was analyzed using the Logrank and Wilcoxon tests. Results -The immunohistochemical expression of p53 was positive in 70 tumors (85.4%) and negative in 12 (14.6%). The expression of bcl-2 was positive in 26 (31.7%) and negative in 56 (68.3%). The expression of Ki-67 was positive in 62 (75.6%) and negative in 20 (24.4%). There was no statistically significant correlation between the expressions of these markers separately or in conjunction, in relation to the degree of cell differentiation, staging, disease-free interval, survival and specific mortality. In relation to recurrence, there was a statistically significant correlation with positive expression of Ki-67 (P = 0.035). Conclusion -The immunohistochemical expression of Ki-67 in colorectal cancer is associated with recurrence of this disease. HEADINGS -Colorectal neoplasms. Adenocarcinoma. Immunohistochemistry. Tumor suppressor protein p53. Proto-oncogene proteins c-bcl-2. Bcl-2 homologous antagonist-killer protein.

Immunohistochemical Expression of Ki67 and HER2 in Colorectal Cancer Compared to Adenomatous and Normal Samples

“…Molecular markers can be useful factors in determining the disease progression, prognosis of patient's condition, and even response to treatments as well as selection of proper therapeutic methods (32). itive Ki67 expression in 62 tumoral samples and negative expressions in 20 other samples, indicating significantly high expression of this protein in CRC samples compared to normal colorectal tissues (33). Above-mentioned studies are consistent with the present study in terms of higher expression of Ki67 protein in colorectal adenocarcinoma samples compared to adenomatous and healthy specimens as well as its gradually increment in different phases of the diseases from the healthy tissue to adenomatous polyps and, ultimately, to colorectal adenocarcinoma.…”

Lack of Relation of AKAP12 with p53 and Bcl-2 in Colorectal Carcinoma

“…In most of the human tumors a relation between Bcl-2 expression and survival has been shown (Yildirim et al, 2012). In studies searching Bcl-2 expression in colon cancer, expression rates were found between 31%-70% (Menezes et al, 2010). In our study; Bcl-2 expression rate was similar to these results.…”

Expression of p53 and DR5 in normal and malignant tissues of colorectal cancer: Correlation with advanced stages

“…Taken together, these data support the finding that when apoptosis is weak, a rapid progression of the disease may be observed (30). Like other published works (30,(35)(36)(37), no correlation between the status of studied proteins and response to treatment of patients was found in our study.…”